Clinical Trial Detail

NCT ID NCT03971474
Title Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Gemcitabine + Pemetrexed Disodium

Docetaxel + Ramucirumab

Docetaxel + Gemcitabine

Pembrolizumab + Ramucirumab

Age Groups: adult senior

No variant requirements are available.